英国支持3 400万英镑的研究,以减少癌症免疫疗法中的致命性免疫反应。 UK backs £3.4M study to reduce deadly immune reaction in cancer immunotherapies.

Poolbeg Pharma的POLB 001试验被选为340万英镑的英国医学研究理事会支持的研究RISE,旨在降低癌症免疫疗法中细胞释放综合症(CRS)的风险。 Poolbeg Pharma’s POLB 001 trial has been selected for a £3.4 million UK Medical Research Council-backed study, RISE, aimed at reducing cytokine release syndrome (CRS) risks in cancer immunotherapies. 该倡议由曼彻斯特大学和Christie NHS基金会信托基金牵头,侧重于改善诸如CAR T细胞和双性抗体疗法等高级治疗的安全性。 The initiative, led by the University of Manchester and The Christie NHS Foundation Trust, focuses on improving the safety of advanced treatments like CAR T-cell and bispecific antibody therapies. Poolbeg的参与利用其在免疫疗法开发方面的专门知识,支持努力使这些有希望但有风险的治疗更安全、更普及。 Poolbeg’s participation leverages its expertise in immunotherapy development, supporting efforts to make these promising but risky treatments safer and more widely available.